CMS proposes 15% Medicare lab fee cuts, impacting Quest Diagnostics and Labcorp
The Centers for Medicare & Medicaid Services (CMS) has proposed a 15% reduction in Medicare lab fees. This potential policy change is reported to put the revenue of major diagnostic companies, including Quest Diagnostics (DGX) and Labcorp (LH), at risk, leading to a decline in their stock prices.
3 articles from 1 outlet covered this story. The underlying claim is sourced from a press release.
What do all outlets agree on?
1 outlet covered “CMS proposes 15% Medicare lab fee cuts, impacting Quest Diagnostics and Labcorp”. All of them report the following:
- CMS targets 15% Medicare lab fee cuts
- Cuts put DGX (Quest Diagnostics) revenue at risk
- Cuts put LH (Labcorp) revenue at risk
- Quest Diagnostics stock is sliding
- Labcorp stock is sliding
Which outlets covered this?
All 3 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.
pragmatist3